title: Bortezomib-induced tumor lysis syndrome in multiple myeloma.
abstract: Tumor lysis syndrome (TLS) is exceedingly rare in multiple myeloma because of the relatively slow proliferation and response of the malignant cells. Bortezomib is a novel agent that inhibits proteasome and has shown activity against multiple myeloma. We report 8 episodes of TLS seen in 7 patients with bortezomib therapy, with or without dexamethasone, among 496 patients treated on 3 phase II multicenter studies. Biochemical abnormalities resolved with supportive therapy in 6 patients (including hemodialysis in 2) but proved fatal in 1. Clinicians should be alert for TLS in patients with myeloma with significant disease burden treated with bortezomib because of the potential for rapid onset of cell lysis with this agent.
authors.affiliation: Department of Hematology and Oncology, University Hospital Charité Berlin, Germany. sezer@charite.de
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezer
authors.forename: David H
authors.initials: DH
authors.lastname: Vesole
authors.forename: Seema
authors.initials: S
authors.lastname: Singhal
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
authors.forename: Edward
authors.initials: E
authors.lastname: Stadtmauer
authors.forename: Christian
authors.initials: C
authors.lastname: Jakob
authors.forename: Anthony L
authors.initials: AL
authors.lastname: Boral
authors.forename: Dixie-Lee
authors.initials: DL
authors.lastname: Esseltine
authors.forename: Jayesh
authors.initials: J
authors.lastname: Mehta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D049109:Cell Proliferation; D002872:Chromosome Deletion; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics; D011480:Protease Inhibitors / Q000494:pharmacology; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000175:diagnosis* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone